D. E. Shaw & Co., Inc. Cure Vac N.V. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Cure Vac N.V. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 206,355 shares of CVAC stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

206,355

Holding current value

$1.11 Million

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.59 - $5.6 $534,459 - $1.16 Million	206,355 New	206,355 $1.12 Million
Q4 2024 Feb 14, 2025	BUY	$2.49 - $3.41 $48,291 - $66,133	19,394 New	19,394 $66,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.34 $641,631 - $947,170	218,242 Added 78.63%	495,780 $1.5 Million
Q4 2023 Feb 14, 2024	BUY	$3.96 - $6.41 $1.1 Million - $1.78 Million	277,538 New	277,538 $1.17 Million
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $350,152 - $517,616	60,896 Added 111.06%	115,726 $697,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $213,352 - $434,690	-28,523 Reduced 34.22%	54,830 $432,000
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $935,661 - $1.38 Million	70,991 Added 574.27%	83,353 $1.13 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $75,432 - $180,515	5,121 Added 70.72%	12,362 $242,000
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $316,023 - $451,917	-9,372 Reduced 56.41%	7,241 $248,000
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $68,766 - $104,002	-1,396 Reduced 7.75%	16,613 $907,000
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $1.02 Million - $2.3 Million	18,009 New	18,009 $1.32 Million
Q1 2021 May 17, 2021	SELL	$79.79 - $126.29 $6.65 Million - $10.5 Million	-83,337 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $3.9 Million - $11.4 Million	83,337 New	83,337 $6.76 Million

Others Institutions Holding CVAC

# of Institutions

102

Shares Held

14.2M

Call Options Held

270K

Put Options Held

114K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $1B
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account